Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Curing Methods01:26

Curing Methods

380
Concrete members with a small surface-to-volume ratio are cured by oiling and moistening the forms before casting the concrete member. These forms can be left in place for a prolonged period to prevent moisture loss, and can be wetted if made of a material suitable for wetting. If the forms are removed early, the concrete member is moistened and covered with polythene sheets to maintain moisture. For large horizontal concrete surfaces exposed to dry weather, a temporary covering is suspended...
380
Curing of Concrete01:20

Curing of Concrete

1.3K
The hydration of cement takes place within the water-filled capillary pores. However, environmental elements can disrupt this process by evaporating water from the concrete surfaces. Sealed concrete with a water-cement ratio below 0.5 experiences self-desiccation, leading to water loss. The water loss in concrete is mitigated by curing. This technique involves keeping the concrete saturated to maintain the necessary temperature and moisture conditions, to optimally fill the spaces in the cement...
1.3K
Therapeutic Index01:13

Therapeutic Index

7.7K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.7K
Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

1.8K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.8K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

637
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
637
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

267
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
267

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Readiness to Consider and Adopt Genetic and Genomic Tests in Canada-An Update to the State of Readiness Report.

Current oncology (Toronto, Ont.)·2026
Same author

Life Years Gained and Healthcare Dollars Saved: National Economic Evidence Supporting Comprehensive Genomic Profiling as Standard of Care for Canadian Cancer Patients.

Current oncology (Toronto, Ont.)·2026
Same author

Points to consider for incorporating climate impacts into health economic evaluation.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same author

Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada.

Expert review of pharmacoeconomics & outcomes research·2025
Same author

Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations.

PharmacoEconomics - open·2024
Same author

Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective.

Current oncology (Toronto, Ont.)·2024

Related Experiment Video

Updated: Apr 14, 2026

Evaluation of the Curing of Adhesive Systems by Rheological and Thermal Testing
09:06

Evaluation of the Curing of Adhesive Systems by Rheological and Thermal Testing

Published on: July 3, 2020

7.9K

How do we value a cure?

Don Husereau1

  • 1Institute of Health Economics, 879 Winnington Ave, Ottawa, ON, Canada.

Expert Review of Pharmacoeconomics & Outcomes Research
|April 28, 2015
PubMed
Summary

Societal valuation of cures will likely mirror current debates on funding prevention versus treatment. Expect similar scrutiny for curative therapies as for other healthcare interventions, considering psychological factors and opportunity costs.

Keywords:
consumer behavior/economicsdiffusion of innovationfinancial/economicshealthinsurancepatient preference/economicsreimbursementreimbursement mechanismsrisk sharing

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.1K
Author Spotlight: Understanding Cytokine-Induced Cell Death in Intestinal Epithelial Cells Using Human Organoids
10:03

Author Spotlight: Understanding Cytokine-Induced Cell Death in Intestinal Epithelial Cells Using Human Organoids

Published on: August 2, 2024

2.0K

Related Experiment Videos

Last Updated: Apr 14, 2026

Evaluation of the Curing of Adhesive Systems by Rheological and Thermal Testing
09:06

Evaluation of the Curing of Adhesive Systems by Rheological and Thermal Testing

Published on: July 3, 2020

7.9K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.1K
Author Spotlight: Understanding Cytokine-Induced Cell Death in Intestinal Epithelial Cells Using Human Organoids
10:03

Author Spotlight: Understanding Cytokine-Induced Cell Death in Intestinal Epithelial Cells Using Human Organoids

Published on: August 2, 2024

2.0K

Area of Science:

  • Health economics
  • Medical decision-making
  • Societal health preferences

Background:

  • Current healthcare funding debates focus on prevention vs. treatment and orphan drugs.
  • Societal valuation of curative therapies compared to standard treatments is not well understood.
  • Psychological factors and opportunity costs significantly influence healthcare funding decisions.

Purpose of the Study:

  • To explore future societal perceptions of curative therapy value.
  • To identify potential tensions between payers and the public regarding curative therapy funding.
  • To determine if curative therapies will face different valuation measures than existing treatments.

Main Methods:

  • Analysis of current debates on healthcare funding preferences.
  • Consideration of psychological factors influencing public perception.
  • Evaluation of opportunity costs in healthcare resource allocation.

Main Results:

  • Future valuation of curative therapies will likely be influenced by ongoing discussions on funding prevention and treatment programs.
  • Societal preferences and psychological factors, alongside opportunity costs, will create tension in curative therapy valuation.
  • Curative therapies are unlikely to be evaluated by a different standard than current medical interventions.

Conclusions:

  • Further research is needed to clarify societal preferences and healthcare goals for curative therapies.
  • Understanding opportunity costs is crucial for evaluating curative therapies.
  • Expect curative therapies to be subject to the same valuation metrics as prevention and treatment measures.